Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-15
2010-11-02
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S145000
Reexamination Certificate
active
07825153
ABSTRACT:
A low concentration formulation for hydrophobic photosensitizers (PS) and method for photodynamic therapy (“PDT”) using the disclosed low concentration formulations provide for more accurate, more efficient and more convenient dosing. The inventive formulation (1) reduces the time for a therapeutically effective level of photosensitizer to accumulate in diseased tissue and (2) reduces the time for achieving a sufficient ratio of photosensitizer in diseased tissue vs. healthy tissue. The inventive formulation reduces the time interval between PS application/administration and irradiation (the drug-light interval or “DLI”) and can provide for a “same day” PDT treatment option. 0.08 mg/ml to 1.3 mg/ml meta Tetra-Hydroxy-Phenyl Chlorin (m-THPC) as the photosensitizer in a mixture of pure propylene glycol and ethanol (3:2 volume ratio) accumulates in diseased tissue and differentiates between diseased tissue and normal tissue sufficiently quickly for ‘one day’ or overnight administration and activation treatment procedures to be possible.
REFERENCES:
patent: 4017501 (1977-04-01), Gordon et al.
patent: 4992257 (1991-02-01), Bonnett et al.
patent: 5162519 (1992-11-01), Bonnett et al.
patent: 5173504 (1992-12-01), Dougherty
patent: 5214036 (1993-05-01), Allison et al.
patent: 5399583 (1995-03-01), Levy et al.
patent: 5492924 (1996-02-01), Gatt et al.
patent: 5576013 (1996-11-01), Williams et al.
patent: 5616342 (1997-04-01), Lyons
patent: 5877165 (1999-03-01), Miura et al.
patent: 6090788 (2000-07-01), Lurie
patent: 6270749 (2001-08-01), Blumenkranz et al.
patent: 6462192 (2002-10-01), Robinson et al.
patent: 6609014 (2003-08-01), Allison et al.
patent: 6949581 (2005-09-01), Nifantiev et al.
patent: 6984655 (2006-01-01), Mori et al.
patent: 7001991 (2006-02-01), Faulk
patent: 2003/0083649 (2003-05-01), Margaron et al.
patent: 2003/0125346 (2003-07-01), Buchanan et al.
patent: 2003/0167033 (2003-09-01), Chen et al.
patent: 2004/0147500 (2004-07-01), Brun et al.
patent: 2004/0259810 (2004-12-01), Grierson et al.
patent: WO03/039597 (2003-05-01), None
Desroches et al., Luminescence, 2001, 16, p. 173-178.
Bonnett et al., J. Porphyrins and Phthalocyanines, 2001, 5, p. 652-661.
Hamster Biological Values from www.labdiet.com, accessed Jul. 22, 2009.
Ronn, A.M., et al: “Human Tissue Levels and Plasma Pharmacokinetics of Temoporfin (Foscan, mTHPC)”, Lasers in Medical Science 1996, 11:267-272.
Glanzmann, T., et al: “Pharmacokinetics and pharmacodynamics of tetra(m-hydroxyphenyl)chlorin in the hamster cheek pouch tumor model: comparison with clinical measurements.” Journal of Photochemistry and Photobiology B: Biology 57 (2000) 22-32.
Annex I, Summary of Product Characteristics: Foscan 1 mg/ml solution for injection, 2006.
Ris H-B, et al: “Photodynamic therapy with mTHPC and polyethylene glycol-derived mTHPC: a comparative study on human tumour xenografts.” British Journal of Cancer (1999) 79(7/8), 1061-1066.
Albrecht Volker
Nifantiev Nikolay
BJ Associates
CeramOptec Industries Inc.
Hartley Michael G
Skutnik Bolesh J.
Westerberg Nissa M
LandOfFree
Photosensitizer formulations and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Photosensitizer formulations and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Photosensitizer formulations and their use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4180348